Obtaining optimal outcomes in the ‘post-antibacterial era’ Paul Chrisp Newsletter Article 08 February 2013 Pages: 3 - 4
Valuing different types of antimicrobial drug formulary Newsletter Article 08 February 2013 Pages: 5 - 6
US costs of cancer, diabetes mellitus and atherosclerosis Newsletter Article 08 February 2013 Pages: 6 - 6
Cost effectiveness of immunising varicella-exposed gravida Newsletter Article 08 February 2013 Pages: 7 - 7
Treatment of mild hypertension cost effective in young? Newsletter Article 08 February 2013 Pages: 8 - 8
Role for community pharmacists in drug formulary development Newsletter Article 08 February 2013 Pages: 8 - 8
Omeprazole more cost effective than H2-antagonists Newsletter Article 08 February 2013 Pages: 10 - 10
NSAIDs + morphine vs coeliac plexus block for cancer pain Newsletter Article 08 February 2013 Pages: 10 - 11
Turn to supply-side reforms to improve outcomes, says WHO Newsletter Article 08 February 2013 Pages: 11 - 11
US company has DM programmes in CHF and hypertension Newsletter Article 08 February 2013 Pages: 11 - 12
Will consumers gain protection over managed-care practices? Newsletter Article 08 February 2013 Pages: 12 - 12